Colorado is currently home to 1912 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06179160
Recruiting
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Sarah Cannon Research Institue At Healthone, Denver, Colorado
Conditions: Solid Tumors
Register for Updates
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650
Recruiting
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypotheses are that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per P... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Colorado Clinical Research ( Site 0067), Lakewood, Colorado
Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Register for Updates
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624
Recruiting
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) and to radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria In Solid Tumors (RECIST 1.1) as assessed by blinded independent central review (BICR) in participants with mCRPC previously treate... Read More
Gender:
All
Ages:
All
Trial Updated:
04/25/2024
Locations: Colorado Clinical Research ( Site 0067), Lakewood, Colorado
Conditions: Prostate Cancer Metastatic
Register for Updates
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06128044
Recruiting
CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in adults with acute myeloid leukemia (AML) that has come back after prior treatment (relapsed) or did not respond or is no longer responding to other treatment (refractory). Participants must have received at least 1 but not more than 3 prior lines of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Colorado Blood Cancer Institute, Denver, Colorado
Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Register for Updates
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491
Recruiting
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Gender:
Male
Ages:
Between 18 years and 130 years
Trial Updated:
04/25/2024
Locations: Research Site, Golden, Colorado
Conditions: Metastatic Castration-Sensitive Prostate Cancer
Register for Updates
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
NCT06020014
Recruiting
This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/25/2024
Locations: Research Site, Denver, Colorado
Conditions: Asthma
Register for Updates
A Study to Access the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
NCT05972044
Recruiting
FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with ADHD.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/25/2024
Locations: Clinical Research Site, Colorado Springs, Colorado
Conditions: ADHD
Register for Updates
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05961839
Recruiting
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Colorado Blood Cancer Institute, Denver, Colorado
Conditions: Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
Register for Updates
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial
NCT05773274
Recruiting
This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus in patients who have previously received 177Lu-DOTATATE for midgut neuroendocrine tumor (NET) that has spread from where it first started (primary site) to other places in the body (metastatic) and that cannot be removed by surgery (unresectable). PRRT is a type of radiation therapy for which a radioactive chemical is linked to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: UCHealth University of Colorado Hospital, Aurora, Colorado
Conditions: Metastatic Midgut Neuroendocrine Tumor, Unresectable Midgut Neuroendocrine Tumor, Metastatic Midgut Neuroendocrine Tumor G1, Metastatic Midgut Neuroendocrine Tumor G2
Register for Updates
NHLBI Transmural Electrosurgery LeafLet Traversal And Laceration Evaluation (TELLTALE) BASILICA-TAVR Trial
NCT05666713
Recruiting
Background: Replacing a valve in the heart can save many people s lives. The procedure is called transcatheter aortic valve replacement (TAVR). In rare cases, a flap of tissue called a leaflet can shift during TAVR; the leaflet may block blood flow to the coronary arteries, which supply blood to the heart muscle. About 50% of people who experience this problem will die. To reduce this risk, doctors will cut this leaflet during TAVR. But the tools used to cut the leaflet were originally designed... Read More
Gender:
All
Ages:
Between 21 years and 109 years
Trial Updated:
04/25/2024
Locations: University of Colorado Health, Fort Collins, Colorado
Conditions: Valvular Heart Disease, Aortic Valve Failure
Register for Updates
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/25/2024
Locations: Denver Arthritis Clinic, Denver, Colorado
Conditions: Systemic Lupus Erythematosus
Register for Updates
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096
Recruiting
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Research Site, Aurora, Colorado
Conditions: Generalized Myasthenia Gravis
Register for Updates